학술논문
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study
Document Type
Artikel
Author
Montesinos, P; Roboz, GJ; Bulabois, CE; Subklewe, M; Platzbecker, U; Ofran, Y; Papayannidis, C; Wierzbowska, A; Shin, HJ; Doronin, V; Deneberg, S; Yeh, SP; Ozcan, MA; Knapper, S; Cortes, J; Pollyea, DA; Ossenkoppele, G; Giralt, S; Dohner, H; Heuser, M; Xiu, L; Singh, I; Huang, F; Larsen, JS; Wei, ARH
Source
Leukemia. 35(1):62-74
Subject
Language
English
English
English
ISSN
1476-5551